| YAP oncogene overexpression supercharges colon cancer proliferation. | colorectal, |
| Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. | lung, |
| Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. | endometrial, |
| Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. | liver, |
| Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. | sarcoma, |
| Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. | None |
| The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. | None |
| PTPN14 interacts with and negatively regulates the oncogenic function of YAP. | None |
| Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. | None |
| G protein-coupled receptors engage the mammalian Hippo pathway through F-actin: F-Actin, assembled in response to Galpha12/13 induced RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene. | None |
| Molecular evolution of the Yap/Yorkie proto-oncogene and elucidation of its core transcriptional program. | None |
| Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. | None |
| Oncoprotein YAP regulates the spindle checkpoint activation in a mitotic phosphorylation-dependent manner through up-regulation of BubR1. | None |